Pacific Biosciences Of California (PACB) Shareholder's Equity Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Shareholder's Equity Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 426.62 Mn | 150.66 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.94% |
| Dec 31, 2025 | -78.82% |
| Sep 30, 2025 | -61.38% |
| Jun 30, 2025 | -55.16% |
| Mar 31, 2025 | -50.03% |
| Dec 31, 2024 | -13.80% |
| Jun 30, 2024 | 24.03% |
| Mar 31, 2024 | 32.26% |
| Dec 31, 2023 | 27.86% |
| Sep 30, 2023 | 80.67% |
| Jun 30, 2023 | 149.39% |
| Mar 31, 2023 | 125.44% |
| Dec 31, 2022 | 117.22% |
| Sep 30, 2022 | 130.73% |
| Jun 30, 2022 | 108.02% |
| Mar 31, 2022 | 97.85% |
| Dec 31, 2021 | 90.70% |
| Jun 30, 2021 | 44.57% |
| Mar 31, 2021 | 39.77% |
| Dec 31, 2020 | 57.36% |